Patiromer's potassium-lowering effect in patients with hyperkalemia is similar regardless of whether or not they are taking renin-angiotensin-aldosterone system inhibitors
Study suggests the optimal range is 3.36 to 5.18 mmol/L in CKD stage 3 and 3.26 to 5.53 mmol/L in CKD stages 4 to 5.
A single 30-gram oral dose of sodium polystyrene sulfonate resulted in a significant decrease in serum potassium within 24 hours.
Rates of hyperkalemia associated with receipt of renin-angiotensin-aldosterone system inhibitors vary by age and comorbidities.
Longitudinal study with preplanned serum potassium measurements may provide a more accurate estimate of the burden of hyperkalemia among CKD patients.
Sodium zirconium cyclosilicate exchanges potassium for sodium and hydrogen throughout the gastrointestinal tract.
Study characterizes the link between admission potassium levels and in-hospital mortality overall and among CKD and CVD patients.
Updated label for patiromer now recommends the drug be taken at least 3 hours before or after other oral medications.
Sodium zirconium cyclosilicate treatment for 12 months had no clinically meaningful effects on systolic or diastolic pressure, study finds.
The risks of death from any cause were elevated by 22% and 31% for individuals with serum potassium levels of 5.5 mmol/L and 3.2 mmol/L, respectively, compared with 4.2 mmol/L.
Lack of association observed in study of hypertensive patients with normal renal function.
Newer potassium binders might have a role in treating the condition, according to a panel.
In patients with chronic kidney disease, the risk of a potential small rise in calcium absorption should be weighed against the risk of hyperkalemia.
Use of a mineralocorticoid receptor antagonist plus a renin-angiotensin-system inhibitor found to increase hyperkalemia risk 3-fold.
A plant-based diet might one day prove to be an option for kidney disease patients.
Add-on mineralocorticoid receptor antagonist therapy increased serum potassium by 0.4 mEq.
Study demonstrates a novel effect of patiromer treatment in hyperkalemic CKD patients
In a large study, high potassium levels were associated with a significant 24% increased risk of death compared with normal levels.
Researchers found a 16% lower risk for strokes, heart attacks, and death combined among patients who took ACEIs or ARBs.
High potassium levels associated with the use of renin-angiotensin-aldosterone system inhibitors limit their use in CKD patients.
As elderly patients age, the number of drugs they take that may cause hyperkalemia increases.
Mortality no different for early versus delayed strategy for patients with severe acute kidney injury.
Systematic review finds that 10 units of short-acting insulin given intravenously may be used in cases of acute hyperkalemia.
The association between potassium levels and mortality, however, was similar among races.
A single 60g oral dose of sodium polystyrene sulfonate found effective in lowering potassium without causing post-treatment hypokalemia.
In-hospital mortality risk was more than double among patients whose hyperkalemia persisted than those whose potassium levels normalized.
Treatment with angiotensin-converting enzyme inhibitors was most strongly associated with hyperkalemia.
The addition of aliskiren to enalapril led to more adverse events in patients with chronic heart failure without an increase in benefit.
Researchers argue that little evidence exists to support this approach to prevent hyperkalemia.
Study finds no significant difference in the rates of all-cause mortality, major cardiac events, and hospital admission with hyperkalemia or AKI.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)